ArticleFrontiers in endocrinology2025
Relationship between plasma atherogenic index and subclinical hypothyroidism: an analysis of NHANES data and animal experiment.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between subclinical hypothyroidism (SCH) and dyslipidemia is established, but that between the atherogenic index of plasma (AIP) and SCH remains unknown. This study aimed to investigate this association by combining an analysis of NHANES data with experimental evidence from an animal experiment. Methods: Cross-sectional data from 3,135 adults were analyzed. Weighted regression and linear models assessed associations between AIP (and its quartiles) and SCH and thyroid hormones. Restricted cubic splines (RCS) tested nonlinearity. Mediation analysis was utilized to identify the mediating effects of thyroid-stimulating hormone (TSH). Subgroup analyses and interaction tests were employed to explore the association between AIP and SCH. To validate these findings, a Sprague-Dawley rat model was established with a high-fat diet and the rats were divided into a control group (CG) and a model group (MG). Blood Lipid, AIP and thyroid function (TSH, FT3, FT4) were measured in each group. Results: After multivariable adjustment, the highest AIP quartile (Q4) significantly correlated with higher SCH prevalence. Elevated AIP associated with decreased free tetraiodothyronine (FT4) and increased total thyroxine (TT4), free triiodothyronine (FT3), total triiodothyronine (TT3), and TSH. RCS showed linear relationships of AIP with SCH, FT4, FT3, and TSH, but nonlinear with TT3 and TT4. Additionally, mediation analysis indicated that TSH accounted for 39.76% of the observed association between AIP and SCH. Animal experiments confirmed that compared with the CG, rats in the MG exhibited significantly higher levels of blood lipid, AIP and TSH, but lower levels of FT4 and FT3. Conclusion: Elevated AIP is significantly associated with a higher prevalence of SCH, and TSH is an interrelated factor in this association. Experimental evidence also shows a link between AIP elevation and thyroid homeostasis disruption, suggesting a relationship between AIP and thyroid dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.